CervoMed Inc. 10-Q

ITEM 5. OTHER INFORMATION   On November 8, 2021, we entered into a Deed of Lease Termination Agreement with the Carlton Landlord providing for the early termination of the Carlton Lease related to our prior corporate headquarters. The Carlton Lease was previously scheduled to expire on April 30, 2022 and, as of September 30, 2021, our aggregate amount of future minimum rental payments thereunder was approximately $69,536. In connection with the termination, we will make a one-time payment to the Carlton Landlord of approximately $14,000, after deducting anticipated returns of deposits in accordance with the Carlton Lease.   In addition to the economic savings, our decision to terminate the Carlton Lease early was also driven by our more general embrace of the remote work culture that became prevalent at many organizations during the COVID-19 pandemic.  We believe our people are critical to our ability to efficiently and successfully execute our stated strategy, and that a remote operating paradigm allows us to enhance our available pool of talented human resources while also conserving financial resources.   We also believe in the value of collaboration.  In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, we have recently entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania. We believe these arrangements will permit our team to combine the advantages of remote and in-person work in environments intended to foster creativity and innovation.     ITEM 6. EXHIBITS   See attached Exhibit Index.   24     DIFFUSION PHARMACEUTICALS INC. QUARTERLY REPORT ON FORM 10-Q EXHIBIT INDEX   Exhibit No. Description Method of Filing 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a) Filed herewith 31.2 Certification of principal financial officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a) Filed herewith 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 32.2 Certification of principal financial officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 101 The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended September 30, 2021 formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Unaudited Interim Consolidated Balance Sheets, (ii) the Unaudited Interim Consolidated Statements of Operations, (iii) the Unaudited Interim Consolidated Statement of Changes in Stockholders’ Equity, (iv) the Unaudited Interim Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Interim Consolidated Financial Statements Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)     25     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: November 10, 2021       DIFFUSION PHARMACEUTICALS INC.                           By: /s/ Robert J. Cobuzzi, Jr.       Robert J. Cobuzzi, Jr.       President and Chief Executive Officer       (Principal Executive Officer)                     By: /s/ William Hornung       William Hornung       Chief Financial Officer       (Principal Financial Officer and Principal Accounting Officer)     26